Brigimadlin
As of the edition of 20 October 2026, Brigimadlin is a small molecule: in active development; acts on MDM2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2030
- Kind
- Small molecule
- Registered trials
- 11, 2 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Hormones; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MDM2 | E3 ubiquitin-protein ligase Mdm2 | Q00987 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 3 | 1 | 1 | 1 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2018 to now |